| Granulomatous infectious diseases associated with tumor necrosis factor antagonists RS Wallis, MS Broder, JY Wong, ME Hanson, DO Beenhouwer Clinical infectious diseases 38 (9), 1261-1265, 2004 | 1232 | 2004 |
| Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice RS Wallis, M Pai, D Menzies, TM Doherty, G Walzl, MD Perkins, A Zumla The lancet 375 (9729), 1920-1937, 2010 | 644 | 2010 |
| The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement I Solovic, M Sester, JJ Gomez-Reino, HL Rieder, S Ehlers, HJ Milburn, ... European Respiratory Journal 36 (5), 1185-1206, 2010 | 607 | 2010 |
| High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial MJ Boeree, N Heinrich, R Aarnoutse, AH Diacon, R Dawson, S Rehal, ... The Lancet infectious diseases 17 (1), 39-49, 2017 | 414 | 2017 |
| Depressed T-cell interferon-γ responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy CS Hirsch, Z Toossi, C Othieno, JL Johnson, SK Schwander, S Robertson, ... Journal of Infectious Diseases 180 (6), 2069-2073, 1999 | 383 | 1999 |
| Host-directed therapies for infectious diseases: current status, recent progress, and future prospects A Zumla, M Rao, RS Wallis, SHE Kaufmann, R Rustomjee, P Mwaba, ... The Lancet Infectious Diseases 16 (4), e47-e63, 2016 | 334 | 2016 |
| Advancing host-directed therapy for tuberculosis RS Wallis, R Hafner Nature Reviews Immunology 15 (4), 255-263, 2015 | 331 | 2015 |
| Tumour necrosis factor antagonists: structure, function, and tuberculosis risks RS Wallis The Lancet infectious diseases 8 (10), 601-611, 2008 | 327 | 2008 |
| Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers RS Wallis, M Maeurer, P Mwaba, J Chakaya, R Rustomjee, GB Migliori, ... The Lancet infectious diseases 16 (4), e34-e46, 2016 | 322 | 2016 |
| A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis MZ Imperial, P Nahid, PPJ Phillips, GR Davies, K Fielding, D Hanna, ... Nature medicine 24 (11), 1708-1715, 2018 | 317 | 2018 |
| Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection JD Simmons, CM Stein, C Seshadri, M Campo, G Alter, S Fortune, ... Nature Reviews Immunology 18 (9), 575-589, 2018 | 317 | 2018 |
| Biomarkers for tuberculosis disease activity, cure, and relapse RS Wallis, TM Doherty, P Onyebujoh, M Vahedi, H Laang, O Olesen, ... The Lancet infectious diseases 9 (3), 162-172, 2009 | 316* | 2009 |
| Tuberculosis biomarkers discovery: developments, needs, and challenges RS Wallis, P Kim, S Cole, D Hanna, BB Andrade, M Maeurer, M Schito, ... The Lancet infectious diseases 13 (4), 362-372, 2013 | 302 | 2013 |
| Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection DE Furst, R Wallis, M Broder, DO Beenhouwer Seminars in arthritis and rheumatism 36 (3), 159-167, 2006 | 276 | 2006 |
| A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis RS Wallis, P Kyambadde, JL Johnson, L Horter, R Kittle, M Pohle, ... Aids 18 (2), 257-264, 2004 | 274 | 2004 |
| Granulomatous infections due to tumor necrosis factor blockade: correction RS Wallis, M Broder, J Wong, D Beenhouwer Clinical Infectious Diseases 39 (8), 1254-1255, 2004 | 269 | 2004 |
| Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity OY Saliu, C Sofer, DS Stein, SK Schwander, RS Wallis The Journal of infectious diseases 194 (4), 486-492, 2006 | 254 | 2006 |
| Reactivation of latent granulomatous infections by infliximab RS Wallis, M Broder, J Wong, A Lee, L Hoq Clinical Infectious Diseases 41 (Supplement_3), S194-S198, 2005 | 242 | 2005 |
| Human immune response to Mycobacterium tuberculosis antigens DV Havlir, RS Wallis, WH Boom, TM Daniel, K Chervenak, JJ Ellner Infection and immunity 59 (2), 665-670, 1991 | 223 | 1991 |
| Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes TK Blackmore, L Manning, WJ Taylor, RS Wallis Clinical Infectious Diseases 47 (10), e83-e85, 2008 | 214 | 2008 |
Professor Sir Alimuddin ZumlaUniversity College LondonVerified email at ucl.ac.uk